Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

US Patent 11566076 · Granted Jan 31, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

IL31-binding polypeptides and uses thereof2025
Method of making afucosylated anti-FGFR2IIIB antibodies2025
CD80 extracellular domain polypeptides and their use in cancer treatment2025
Compositions and methods for inhibition of the JAK pathway2023
B7-H4 antibodies and methods of use thereof2023
Anticancer agents2023
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for can2023
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for can2023
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for can2023
FGFR2 inhibitors alone or in combination with immune stimulating agents in cance2022
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic2022
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic2022